| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Tango Therapeutics, Inc.
13G/A
Amendment 2
TNGX · 87583X109
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| Nextech Crossover I GP S.a. r.l. | 0% | ||||
| Nextech Crossover I SCSp | 0% | ||||
| Ian Charoub | 0% | ||||
| Costas Constantinides | 0% | ||||
| Rocco Sgobbo | 0% | ||||
|
Tango Therapeutics, Inc.
13G/A
Amendment 1
TNGX · 87583X109
|
5.1% |
5/15/2026
Event 3/31/2026
|
|||
| Nextech Crossover I GP S.a. r.l. | 5.1% | ||||
| Nextech Crossover I SCSp | 5.1% | ||||
| Ian Charoub | 5.1% | ||||
| Costas Constantinides | 5.1% | ||||
| Rocco Sgobbo | 5.1% | ||||
|
Mersana Therapeutics, Inc.
13G/A
Amendment 3
MRSN · 59045L205
|
0% |
1/9/2026
Event 1/6/2026
|
|||
| Nextech Crossover I GP S.a. r.l. | 0% | ||||
| Nextech Crossover I SCSp | 0% | ||||
| Ian Charoub | 0% | ||||
| Costas Constantinides | 0% | ||||
| Rocco Sgobbo | 0% | ||||
|
ORIC Pharmaceuticals, Inc.
13G/A
Amendment 2
ORIC · 68622P109
|
8.4% |
8/14/2025
Event 6/30/2025
|
|||
| Nextech Crossover I GP S.a. r.l. | 8.4% | ||||
| Nextech Crossover I SCSp | 8.4% | ||||
| Ian Charoub | 8.4% | ||||
| Costas Constantinides | 8.4% | ||||
| Rocco Sgobbo | 8.4% | ||||
|
Mersana Therapeutics, Inc.
13G/A
Amendment 2
MRSN · 59045L106
|
10.4% |
12/26/2024
Event 12/20/2024
|
|||
| Nextech Crossover I GP S.a. r.l. | 10.4% | ||||
| Nextech Crossover I SCSp | 10.4% | ||||
| Ian Charoub | 10.4% | ||||
| Costas Constantinides | 10.4% | ||||
| Rocco Sgobbo | 10.4% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.